Ustekinumab: Effective in a patient with severe recalcitrant generalized pustular psoriasis

British Journal of Dermatology

Volumn 163, Issue 6, 2010, Pages 1346-1347

  Dauden E ^a   Santiago Et Sanchez Mateos D ^b   Sotomayor Lopez E ^b   Garcia Diez A ^a,b  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

biologic therapy; pustular psoriasis; ustekinumab

Indexed keywords

BETAMETHASONE; CALCIPOTRIOL; EFALIZUMAB; ETRETIN; ETRETINATE; INFLIXIMAB; METHOTREXATE; PSORALEN; RETINOID DERIVATIVE; USTEKINUMAB;

ADULT; CASE REPORT; DRUG WITHDRAWAL; ERYTHEMA; HUMAN; LETTER; MALE; PRIORITY JOURNAL; PUSTULAR PSORIASIS; PUSTULE; SCORING SYSTEM; SKIN BIOPSY; SKIN DEFECT; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; BIOPSY; HUMANS; IMMUNOLOGIC FACTORS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; PSORIASIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 78649674113     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2010.09995.x     Document Type: Letter

References (8)

1. Krueger GG, Langley RG, Leonardi C, et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 2007; 356: 580-92.
2. Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomized, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008; 371: 1665-74.
3. Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomized, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008; 371: 1675-84.
4. Griffiths EM, Strober BE, Van de Kerkhof P, et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 2010; 362: 118-28.
5. Palomo A, Torres LM, Cervigón I, Gil B,. Generalized pustular psoriasis: treatment with etanercept. Med Cutan Ibero Lat Am 2009; 37: 224-6.
6. Lopez-Estebaranz JL, Ruiz-Genao D,. Pustular psoriasis, palmoplantar psoriasis, erythrodermal psoriasis and etanercept. Actas Dermosifiliogr 2010; 101 (Suppl. 1): 35-9.
7. Aslanidis S, Pyrpasopoulou A, Douma S, Triantafyllou A,. Tumor necrosis factor-a antagonist-induced psoriasis: yet another paradox in medicine. Clin Rheumatol 2008; 27: 377-80.
8. Collamer A, Guerrero KT, Henning J, Battafarano D,. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthritis Rheum 2008; 59: 996-1001.